Marchex Q2 Revenue Dips 6% but Pro Forma Archenia Combo Shows $15.5M and Positive EBITDA
MCHX sits 32% above its 52-week low of $1.322 on light trading volume (0.2× avg).
Summary
Marchex's Q2 results show a revenue decline but strong pro forma combined performance with Archenia, positive EBITDA, and encouraging customer adoption metrics.
Key Events · Earnings and Guidance · MCHX
-
Q2 Revenue Declines 6%
Revenue was $11.0 million for Q2 2026, compared to $11.7 million for Q2 2025.
-
Pro Forma Combined Revenue Reaches $15.5M
Including Archenia, pro forma combined revenue for Q2 2026 was $15.5 million with adjusted EBITDA of $1.0 million.
-
Q3 Guidance Shows Growth
Company expects Q3 2026 pro forma revenue of $16.0-$16.5 million and adjusted EBITDA of $2.3-$2.5 million.
-
Customer Adoption Momentum
Existing home services client increased annualized revenue from $500K to over $1M after adopting Archenia's AI-verified outcomes.
Analysis · MCHX · Technology
Marchex reported Q2 2026 revenue of $11.0 million, down 6% year-over-year, with a net loss of $0.4 million. However, the pro forma combined results including Archenia show revenue of $15.5 million and adjusted EBITDA of $1.0 million, indicating the acquisition is already contributing meaningfully. The company provided Q3 guidance of $16.0-$16.5 million in revenue and $2.3-$2.5 million in adjusted EBITDA, suggesting continued momentum. Early customer adoption examples show existing clients expanding spend significantly, which supports the strategic rationale for the Archenia deal.
At the time of this filing, MCHX was trading at $1.75 on NASDAQ in the Technology sector, with a market capitalization of approximately $77.6M. The 52-week trading range was $1.32 to $2.09. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.